Clinical Trials

The purpose of this study is to answer whether plasma circulating tumor DNA (ctDNA) obtained by serial analysis before, during, and following surgery, radiotherapy, chemotherapy, and/or immunotherapy for cervical cancer will allow for risk stratification, individualized treatment decision making, monitoring of treatment response, and early detection of residual or recurrent disease in patients presenting with human papillomavirus (HPV) mediated cervical cancer.

1. Salivary tumor DNA (stDNA) and the HPV self-test for oncogenic HPV (self-test) will be detectable in patients with human papillomavirus associated oropharyngeal squamous cell carcinoma (HPV(+)OPSCC) and not in HPV(-)OPSCC, oral cavity cancer or normal controls.
    
2. There will be a difference in the microbiome, virome, and metabolomics in normal control patients compared to patients with oropharyngeal cancer or oral cavity cancer.
    
3. There will be a difference in patient reported risk factors between patients with malignancy and normal controls.
    
4. There will be dynamic changes in the microbiome and metabolomics which correspond with patient reported outcomes in patients with oropharyngeal cancer or ...

The purposes of this study are to assess awareness and acceptability of HPV testing for cervical cancer screening and patient self-collection of vaginal swabs among women aged 30 to 65 years old, to assess awareness and acceptability of HPV testing for cervical cancer screening and patient self-collection of vaginal swabs among primary care clinicians, and to identify insights from regional and national thought leaders in the fields of primary care and cervical cancer screening on strategies to improve uptake of primary HPV screening and opinions on patient self-collection by conducting key informant interviews. 

The purpose of this study is to test whether our developed real-time HPV detection platform (HPView) performs at a comparable level to the clinical gold-standard.